Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pantoprazole Clear all
Completed Phase 4 Interventional

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

NCT00304421
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole, pantoprazole
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 1 Interventional

Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants

NCT00744419
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 11 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 23, 2026, 8:07 PM EDT
Terminated Not applicable Interventional Results available

Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed

NCT02235311
View directory record Official record
Conditions
Upper Gastrointestinal Bleed
Interventions
Pantoprazole
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

NCT06154226
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Pantoprazole, Famotidine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 23, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available

Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

NCT05251233
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor, Pancreatitis, Distal Extrahepatic Cholangiocarcinoma, Duodenal Cancer
Interventions
Placebo, Pantoprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 1 Interventional Results available

PK Study With Pantoprazole in Obese Children and Adolescents

NCT02186652
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pantoprazole
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Little Rock, Arkansas • Kansas City, Missouri • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 23, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery

NCT06488001
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 79 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 23, 2026, 8:07 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients

NCT06531642
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days, Protonix (pantoprazole) 40 mg q 24 hrs for 2 days
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

NCT01848457
View directory record Official record
Conditions
Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions
Pantoprazole, High-dose methotrexate infusion duration
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 4 Interventional

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

NCT00246909
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Pantoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore the Effect of Acid-reducing Agents

NCT04935112
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib, Pantoprazole, Famotidine
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT00259012
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole sodium enteric-coated spheroid suspension
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Month to 11 Months
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 4 Interventional Results available

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

NCT03094416
View directory record Official record
Conditions
Hypothyroidism;Postablative
Interventions
levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Ventura, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study

NCT01887743
View directory record Official record
Conditions
Obesity, GERD
Interventions
Pantoprazole
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD

NCT00362609
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Day to 28 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Sep 23, 2026, 8:07 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection

NCT02788591
View directory record Official record
Conditions
Non-erosive Reflux Disease, Gastroesophageal Reflux
Interventions
Proton Pump Inhibitor (PPI) Therapy, Sucralfate
Drug
Lead sponsor
LCMC Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

NCT00674245
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pantoprazole, placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 23, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

NCT06706258
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 3 Interventional

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophagitis
Interventions
Pantoprazole for approximately 9 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 23, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 23, 2026, 8:07 PM EDT